Trial Profile

A Phase 1, Open-label, Single-centre Study Investigating the Effect of C21 on Forearm Blood Flow in Healthy Male Subjects by Use of Strain-gauge Venous Occlusion Plethysmography

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 30 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Buloxibutid (Primary) ; Sodium nitroprusside
Indications Idiopathic pulmonary fibrosis
Focus Therapeutic Use
Sponsors Vicore Pharma

Most Recent Events

11 Nov 2022 Status changed from active, no longer recruiting to completed.
21 Sep 2022 Primary endpoint (Change from baseline in forearm blood flow in response to increasing intraarterial doses of C21) has been met, according to a Vicore Pharma media release.
21 Sep 2022 Results published in the Vicore Pharma Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com